Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Biological: cixutumumab
Drug: carboplatin
Drug: paclitaxel
Biological: cetuximab

First Posted Date: 2009-09-30

Last Posted Date: 2014-09-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 140

Registration Number: NCT00986674

Locations: 🇺🇸
Greater Baltimore Medical Center, Baltimore, Maryland, United States
🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States

and more 244 locations

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Metastatic Melanoma

First Posted Date: 2009-09-25

Last Posted Date: 2015-04-10

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 14

Registration Number: NCT00984464

Locations: 🇺🇸
Cancer Therapy & Research Center at UTHSCSA, San Antonio, Texas, United States

Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors

Phase 1

Conditions: Germ Cell Tumor
Recurrent Medulloblastoma
Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
Medulloblastoma
Medulloepithelioma
Recurrent Malignant Germ Cell Tumor
Recurrent Primitive Neuroectodermal Tumor
Primitive Neuroectodermal Tumor
Central Nervous System Embryonal Neoplasm
Recurrent Childhood Central Nervous System Embryonal Neoplasm

Interventions: Drug: Carboplatin
Drug: Mannitol
Drug: Melphalan
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Sodium Thiosulfate

First Posted Date: 2009-09-24

Last Posted Date: 2021-10-26

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 17

Registration Number: NCT00983398

Locations: 🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer

Phase 1

Conditions: Head and Neck Neoplasms

Interventions: Drug: Docetaxel/cisplatin
Radiation: Radiotherapy
Drug: Carboplatin

First Posted Date: 2009-09-23

Last Posted Date: 2012-03-22

Lead Sponsor: University of Vermont

Target Recruit Count: 37

Registration Number: NCT00982436

Locations: 🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States
🇺🇸
Vermont Center for Cancer Medicine, Colchester, Vermont, United States
🇺🇸
Mountainview Medical Center, Berlin, Vermont, United States

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Phase 3

Active, not recruiting

Conditions: Cervical Cancer

Interventions: Drug: cisplatin
Drug: carboplatin
Radiation: intensity-modulated radiation therapy
Radiation: standard external beam radiation therapy
Drug: paclitaxel
Radiation: Optional brachytherapy boost

First Posted Date: 2009-09-21

Last Posted Date: 2024-11-26

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 236

Registration Number: NCT00980954

Locations: 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

and more 122 locations

Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: panitumumab
Drug: paclitaxel
Procedure: surgery

First Posted Date: 2009-09-17

Last Posted Date: 2022-06-15

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 71

Registration Number: NCT00979212

Locations: 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Radiological Associates of Sacramento Medical Group, Incorporated, Sacramento, California, United States
🇺🇸
Mercy Cancer Center at Mercy San Juan Medical Center, Carmichael, California, United States

and more 28 locations

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2

Active, not recruiting

Conditions: Endometrial Clear Cell Adenocarcinoma
Recurrent Uterine Corpus Cancer
Stage IIIA Uterine Corpus Cancer AJCC v7
Endometrial Adenocarcinoma
Endometrial Adenosquamous Carcinoma
Stage IVA Uterine Corpus Cancer AJCC v7
Stage IIIB Uterine Corpus Cancer AJCC v7
Stage IIIC Uterine Corpus Cancer AJCC v7
Endometrial Serous Adenocarcinoma
Stage IVB Uterine Corpus Cancer AJCC v7

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Ixabepilone
Drug: Paclitaxel
Drug: Temsirolimus

First Posted Date: 2009-09-15

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 349

Registration Number: NCT00977574

Locations: 🇺🇸
Henry Ford Health Warren Hospital, Warren, Michigan, United States
🇺🇸
Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

and more 229 locations

Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: bevacizumab
Drug: carboplatin
Drug: everolimus
Drug: paclitaxel

First Posted Date: 2009-09-14

Last Posted Date: 2017-04-04

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 149

Registration Number: NCT00976573

Locations: 🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸
Minnesota Oncology - Woodbury, Woodbury, Minnesota, United States
🇺🇸
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States

and more 304 locations

Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: paclitaxel
Drug: carboplatin
Biological: bevacizumab

First Posted Date: 2009-09-14

Last Posted Date: 2014-05-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT00976677

Locations: 🇺🇸
Illinois CancerCare-Havana, Havana, Illinois, United States
🇺🇸
Mason District Hospital, Havana, Illinois, United States
🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 105 locations

A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: GDC-0941
Drug: carboplatin
Drug: bevacizumab
Drug: paclitaxel
Drug: cisplatin
Drug: pemetrexed

First Posted Date: 2009-09-10

Last Posted Date: 2016-11-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 65

Registration Number: NCT00974584

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy